Adjuvant personalized cancer vaccine: is this the end of metastatic kidney cancer

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2025-03-27 DOI:10.1038/s41585-025-01018-6

Manuela Schmidinger, Irene Huebner-Resch

引用次数: 0

Abstract

The first study of personalized cancer vaccines for renal cell carcinoma with breakthrough results in the adjuvant setting has been published, showing a 100% efficacy rate and negligible toxic effects. However, important questions remain concerning long-term effectiveness.

查看原文本刊更多论文

佐剂个体化癌症疫苗：这是转移性肾癌的终结吗

第一项针对肾细胞癌的个性化癌症疫苗的研究在佐剂设置方面取得了突破性成果，显示100%的有效率和微不足道的毒性作用。然而，关于长期有效性的重要问题仍然存在。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.